Conditional Cash Transfers and Pre- and Post-TB Test Counselling to reduce total loss to follow up across the continuum of care

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410708311054

Enrollment

9740

Registered

2024-10-14

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Counselling and Conditional Cash Transfers

Standard of care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • 18 years of age or older at time of TB screening • Undergoing smear or Xpert sputum investigation for pulmonary TB • Undergoing Xpert or smear investigation for suspected pulmonary TB • Participant able and willing to sign informed consent and are willing to undergo study procedures and visits at the study site

Exclusion criteria

Exclusion criteria: • Younger than 18 years of age • Current diagnosis of PTB at baseline • Receiving TB treatment at baseline • Proxy individual submitting sputum on behalf of patient • Participant anticipates transferring to another facility to receive TB treatment should a diagnosis of PTB be confirmed • Participant anticipates relocating to another Province during the study period

Design outcomes

Primary

Measure	Time frame
The primary outcomes were successful patient outcome (SPO) or unsuccessful patient outcome (USPO). SPO was given to patients who were TB cured or TB completed as per National TB Control guidelines for South Africa. A TB case who experienced one or more of the following was defined as having experienced a failure (USPO) event: •Failure to initiate TB treatment with 14 days of the collection date of the participant’s first TB positive rifampicin-susceptible baseline sample •Death (any cause) within 14 days of collection of Xpert positive TB sample and prior to commencing TB treatment •Death (any cause) whilst receiving TB treatment •Development of RR-TB whilst on treatment •TB treatment failure, defined as smear or culture positive at 5 months or later after commencing TB treatment •Loss to follow up during TB treatment, defined as more than 56 days late for a scheduled appointment	—

Measure

Time frame

The primary outcomes were successful patient outcome (SPO) or unsuccessful patient outcome (USPO). SPO was given to patients who were TB cured or TB completed as per National TB Control guidelines for South Africa. A TB case who experienced one or more of the following was defined as having experienced a failure (USPO) event: •Failure to initiate TB treatment with 14 days of the collection date of the participant’s first TB positive rifampicin-susceptible baseline sample •Death (any cause) within 14 days of collection of Xpert positive TB sample and prior to commencing TB treatment •Death (any cause) whilst receiving TB treatment •Development of RR-TB whilst on treatment •TB treatment failure, defined as smear or culture positive at 5 months or later after commencing TB treatment •Loss to follow up during TB treatment, defined as more than 56 days late for a scheduled appointment

—

Secondary

Measure	Time frame
The secondary outcome was the time to event (time to initiation of treatment and time to loss to follow up).	—

Countries

South Africa

Contacts

Public ContactNazir Ismail

Wits University

nazir.ismail@wits.ac.za+27117172527

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026